Cost Effectiveness Model

Interactive Pneumococcal Vaccination Policy Model

Vaccination of children in developing countries against pneumococcal infection has great potential to save lives and reduce disability. The pneumococcus (Streptococcus pneumoniae) pneumococcus (Streptococcus pneumoniae)is the leading bacterial cause of acute lower respiratory infections, which in turn, are a major cause of child mortality. It also causes meningitis, other forms of invasive bacterial disease, and ear infections (Otitis Mediaotitis media).

The economic burden caused by pneumococcal infection can be great and can be felt on the family, health system, and national level. Routine vaccination of infants against pneumococcus needs substantial investment by governments, non-governmental organizations, and donors.

The Interactive Pneumococcal Conjugate Vaccination Policy Model was developed by infectious disease specialists, computer scientists and decision analysts based at the University of Medicine and Dentistry of New Jersey, in collaboration with the Department of International Health at Johns Hopkins Bloomberg School of Public Health. It underwent an extensive expert review process, drawing on experts in the fields of pneumococcal epidemiology and disease burden, penumococcal conjugate vaccinology, health economics, and policy.

This Interactive Pneumococcal Conjugate Vaccination Policy Model allows the health benefits, costs, and cost-effectiveness of childhood pneumococcal conjugate vaccine to be projected according to an evidence-based approach. It is designed for users with familiarity using personal computers but with limited experience conducting health economic analyses. Wherever possible, the model is pre-populated with inputs drawn from the highest quality data sources.

This model addresses the need for streamlined cost-effectiveness analysis tools to assist decision makers in understanding the economic and health benefits associated with vaccine introductions.

This Interactive Pneumococcal Vaccination Policy Model was developed through an expert panel process. The panel reached consensus on the key assumptions about epidemiology, vaccine efficacy, costs and model outputs projecting the cost-effectiveness of pneumococcal conjugate vaccine for infants in GAVI-eligible countries. Members of the panel were chosen for their expertise in pneumococcal epidemiology, vaccine-related health economics, public health, and/or preventive medicine in GAVI-eligible settings.

To login and begin using the model now, click here.

Expert Panelists

     Dagna Constenla, PhD
          Economic consultant
          Fort Collins, CO, USA
     Felicity Cutts, PhD
          Professor Emeritus
          Infectious Disease Epidemiology Unit
          London School of Hygiene and Tropical Medicine
          Provence, France
     Adam Finn, MD
          David Baum Professor of Paediatrics;
          Head, Unit of Child Health,
          Dept. Clinical Sciences at South Bristol
          Institute of Child Life & Health, University of Bristol
          Bristol, UK
     Andrew Pollard, MD
          Reader in Paediatric Infection and Immunity;
          Consultant in Charge of the Oxford Vaccine Group;
          Head of the Paediatric Infection and Immunity Laboratory
          Department of Paediatrics, University of Oxford
          John Radcliffe Hospital
          Oxford, UK
     G. Tom Ray, MBA
          Senior Analyst
          Division of Research
          Kaiser Permanente
          Oakland, CA, USA
      Cyndy Whitney, MD MPH
          Acting Chief
          Respiratory Diseases Branch, National Center for Infectious Diseases
          Centers for Disease Control and Prevention
          Atlanta, GA, USA

GAVI's PneumoADIP Team

     Julie Buss, MPH
          Communications Manager
     Michelle Moncrieffe-Foreman
          Communications Manager
     Madeline Beal
          Manager, Communications Team
     Maria Deloira Knoll, PhD
          Director of Research
     Orin Levine, PhD
          Executive Director
     Kate O'Brien MD, MPH
          Deputy Director of Research

Investigators/Development Team

          Clinical Assistant Professor
          Department of Medicine
          UMDNJ - Robert Wood Johnson Medical School
          New Brunswick, NJ USA
          cgreg@cgreg.com
      Anushua Sinha, MD MPH
          Assistant Professor of Preventive Medicine and Community Health
          UMDNJ - New Jersey Medical School
          Newark, NJ USA
      Frank Sonnenberg, MD
          Professor of Medicine, Associate Director of Clinical Informatics
          UMDNJ - Robert Wood Johnson Medical School
          New Brunswick, NJ USA

To login and begin using the model now, click here.